Overexpression of Nonconvertible PrPcΔ114–121 in Scrapie-Infected Mouse Neuroblastoma Cells Leads to trans-Dominant Inhibition of Wild-Type PrPSc Accumulation

ABSTRACT One hallmark of prion diseases is the accumulation of the abnormal isoform PrP Sc of a normal cellular glycoprotein, PrP c , which is characterized by a high content of β-sheet structures and by its partial resistance to proteinase K. It was hypothesized that the PrP region comprising amino acid residues 109 to 122 [PrP(109–122)], which spontaneously forms amyloid when it is synthesized as a peptide but which does not display significant secondary structure in the context of the full-length PrP c molecule, should play a role in promoting the conversion into PrP Sc . By using persistently scrapie-infected mouse neuroblastoma (Sc+-MNB) cells as a model system for prion replication, we set out to design dominant-negative mutants of PrP c that are capable of blocking the conversion of endogenous, wild-type PrP c into PrP Sc . We constructed a deletion mutant (PrP c Δ114–121) lacking eight codons that span most of the highly amyloidogenic part, AGAAAAGA, of PrP(109–122). Transient transfections of mammalian expression vectors encoding either wild-type PrP c or PrP c Δ114–121 into uninfected mouse neuroblastoma cells (Neuro2a) led to overexpression of the respective PrP c versions, which proved to be correctly localized on the extracellular face of the plasma membrane. Transfection of Sc+-MNB cells revealed that PrP c Δ114–121 was not a substrate for conversion into a proteinase K-resistant isoform. Furthermore, its presence led to a significant reduction in the steady-state levels of PrP Sc derived from endogenous PrP c . Thus, we showed that the presence of amino acids 114 to 121 of mouse PrP c plays an important role in the conversion process of PrP c into PrP Sc and that a deletion mutant lacking these codons indeed behaves as a dominant-negative mutant with respect to PrP Sc accumulation. This mechanism could form a basis for a new gene therapy and/or a prevention concept for prion diseases.

[1]  S. Prusiner,et al.  Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. , 1993, Glycobiology.

[2]  F E Cohen,et al.  The prion folding problem. , 1997, Current opinion in structural biology.

[3]  S. Prusiner,et al.  Evidence for a secretory form of the cellular prion protein. , 1987, Biochemistry.

[4]  F. Cohen,et al.  Conformational transitions in peptides containing two putative alpha-helices of the prion protein. , 1995, Journal of molecular biology.

[5]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[6]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.

[7]  G. Forloni,et al.  Neurotoxicity of a prion protein fragment , 1993, Nature.

[8]  K Wüthrich,et al.  NMR characterization of the full‐length recombinant murine prion protein, mPrP(23–231) , 1997, FEBS letters.

[9]  D. Harris,et al.  Identification of Intermediate Steps in the Conversion of a Mutant Prion Protein to a Scrapie-like Form in Cultured Cells* , 1997, The Journal of Biological Chemistry.

[10]  B. Chesebro,et al.  Prion protein and the transmissible spongiform encephalopathies. , 1997, Trends in cell biology.

[11]  B. Chesebro,et al.  Characterization of scrapie infection in mouse neuroblastoma cells. , 1987, The Journal of general virology.

[12]  B. Chesebro,et al.  Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells , 1994, Journal of virology.

[13]  A. Aguzzi,et al.  Prion protein (PrP) with amino‐proximal deletions restoring susceptibility of PrP knockout mice to scrapie. , 1996, The EMBO journal.

[14]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[15]  N. C. Price,et al.  Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[16]  R. Riek,et al.  Recombinant full‐length murine prion protein, mPrP(23–231): purification and spectroscopic characterization , 1997, FEBS letters.

[17]  P. Lansbury,et al.  Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. , 1996, Biochemistry.

[18]  B. Chesebro,et al.  Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones , 1988, Journal of virology.

[19]  F. Cohen,et al.  Prion diseases of humans and animals , 1996 .

[20]  A. Hofman,et al.  A new variant of Creutzfeldt-Jakob disease in the UK , 1996, The Lancet.

[21]  S. Prusiner,et al.  Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R J Fletterick,et al.  Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. Cohen,et al.  Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Cousens,et al.  Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent , 1997, Nature.

[25]  Andrew F. Hill,et al.  The same prion strain causes vCJD and BSE , 1997, Nature.

[26]  B. Chesebro,et al.  In vitro expression in eukaryotic cells of a prion protein gene cloned from scrapie-infected mouse brain. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Riek,et al.  NMR structure of the mouse prion protein domain PrP(121–231) , 1996, Nature.

[28]  G. J. Raymond,et al.  The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. , 1991, The Journal of biological chemistry.

[29]  S. Prusiner,et al.  Synthesis and trafficking of prion proteins in cultured cells. , 1992, Molecular biology of the cell.

[30]  G. de Murcia,et al.  Inhibition of poly(ADP-ribosyl)ation by overexpressing the poly(ADP-ribose) polymerase DNA-binding domain in mammalian cells. , 1990, The Journal of biological chemistry.

[31]  F E Cohen,et al.  Prion protein gene variation among primates. , 1997, Journal of molecular biology.

[32]  S. Prusiner,et al.  Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells , 1990, The Journal of cell biology.

[33]  F. Cohen,et al.  Recombinant scrapie-like prion protein of 106 amino acids is soluble. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Fred E. Cohen,et al.  Conformational Transformations in Peptides Containing Two Putative α-Helices of the Prion Protein , 1995 .

[35]  S. Prusiner,et al.  Ultrastructural localization of scrapie prion proteins in cytoplasmic vesicles of infected cultured cells. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[36]  T. Kitamoto,et al.  An amber mutation of prion protein in Gerstmann-Sträussler syndrome with mutant PrP plaques. , 1993, Biochemical and biophysical research communications.

[37]  J. Hauw,et al.  BSE transmission to macaques , 1996, Nature.

[38]  G. Forloni,et al.  Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. , 1997, Science.

[39]  A. Aguzzi,et al.  Normal host prion protein necessary for scrapie-induced neurotoxicity , 1996, Nature.

[40]  S. Prusiner,et al.  Chemical chaperones interfere with the formation of scrapie prion protein. , 1996, The EMBO journal.

[41]  S. Prusiner,et al.  Molecular biology of prion diseases , 1991, Science.

[42]  Andrew F. Hill,et al.  Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD , 1996, Nature.

[43]  Bernhard Schmidt,et al.  Role of microglia and host prion protein in neurotoxicity of a prion protein fragment , 1996, Nature.

[44]  B. Caughey,et al.  Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. , 1991, Biochemistry.

[45]  P. Roller,et al.  Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. , 1993, The Journal of biological chemistry.

[46]  B. Chesebro,et al.  A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells , 1995, Journal of virology.

[47]  C. Locht,et al.  Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Prusiner,et al.  Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells , 1990, The Journal of cell biology.